PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Net income growth similar to AGEN's 28.27%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-0.50%
Negative yoy D&A while AGEN is 82.36%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
15.92%
Deferred tax of 15.92% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
0.65%
SBC growth while AGEN is negative at -7.14%. John Neff would see competitor possibly controlling share issuance more tightly.
-31.26%
Negative yoy working capital usage while AGEN is 172.93%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
Lower AP growth vs. AGEN's 389.92%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-40.45%
Negative yoy usage while AGEN is 840.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-15.92%
Negative yoy while AGEN is 1051.18%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Operating cash flow growth at 75-90% of AGEN's 38.06%. Bill Ackman would recommend further refinements to match competitor’s CFO gains.
100.00%
Lower CapEx growth vs. AGEN's 249.86%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while AGEN is negative at -75.55%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Both yoy lines negative, with AGEN at -50.97%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.